

Oxular announces issued UK Patent related to its proprietary Ocular Drug Composition and Uses

29 May 2019 – Oxular Limited, the Oxford-based retinal therapeutics company, today announced the UK Intellectual Property Office granted GB-B-2536517 in a patent titled “Ophthalmic drug compositions.”

GB-B-2536517 provides a composition for treatment of ophthalmic disease for injection or delivery into tissue spaces of the eye. The composition may comprise a plurality of spherical drug containing particles that disperse in the space to promote uniform drug distribution. The particles may be designed to prolonged release kinetics of the drug.

We strongly believe this drug formulation technology enables Oxular’s unique treatment approach which aims to access specific small spaces in the eye and to provide unique drug distribution to tissues specifically involved in retinal diseases. Drug compositions are paired with a companion drug delivery device to form a complete system which is engineered to meet the demands of current market trends toward longer treatment durations and less invasive delivery.

Enquiries

Ben Atwell

Tel: +44 (0) 2037 271390

About Oxular Limited

Oxular is developing novel retinal treatments engineered to access specific small spaces in the eye and to provide unique drug distribution to tissues specifically involved in retinal diseases. The innovative approach aims to increase therapeutic effectiveness, reduce side-effects and minimize frequency of treatments. Oxular’s product development pipeline includes treatments for prevalent retinal diseases, such as diabetic macular edema, as well as rare and orphan indications (www.oxular.com).